Key opinion leader trends, clinical-trial commentary, conference recaps, and AI-native intelligence on the physicians shaping oncology practice — straight from the social conversation.
Dr. John Heymach provided the Uromigos with a review on the HARMONi-2 trial of ivonescimab in NSCLC
Key Opinion Leader Network Mapping through KOL Pulse AI generated social network visualization of KOL discussions of HARMONi-A from #ASCO24
Akeso biopharma published a preprint of the mechanism of action of ivonescimab. Can the KOL Pulse AI provide context to KOL questions about HARMONi-A?
KOL Pulse turns the oncology social conversation into AI-native intelligence. See it in action.